Early immune responses accompanying human asymptomatic Ebola infections
about
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosisFilovirus research in Gabon and equatorial Africa: the experience of a research center in the heart of AfricaGene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.The Role of Cytokines and Chemokines in Filovirus InfectionFiloviruses: One of These Things is (not) Like the OtherYellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes[Haemostasis dysregulation in filovirus infections].Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic InfectionIdentification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virusEbola virion attachment and entry into human macrophages profoundly effects early cellular gene expression.Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.Camouflage and misdirection: the full-on assault of ebola virus diseaseTreatment of ebola virus disease.Ebola virus infection: what should be known?Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola virusesEbola virus-like particles protect from lethal Ebola virus infection.Are surveillance response systems enough to effectively combat and contain the Ebola outbreak?Evasion of the interferon-mediated antiviral response by filoviruses.Unconventional secretion of Ebola virus matrix protein VP40.Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo.Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.Progress in filovirus vaccine development: evaluating the potential for clinical use.Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.Role of natural killer cells in innate protection against lethal ebola virus infection.Ebola virus does not block apoptotic signaling pathways.Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever.Correlates of immunity to filovirus infection.Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.Characterization of host immune responses in Ebola virus infections.Animal models for ebolavirus countermeasures discovery: what defines a useful model?Association of clinical signs and symptoms of Ebola viral disease with case fatality: a systematic review and meta-analysisEbola Virus Disease in Humans: Pathophysiology and Immunity.Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human.Nonhuman Primate Models of Ebola Virus Disease.Ebola Virus Makona Shows Reduced Lethality in an Immune-deficient Mouse Model.
P2860
Q21144780-E9935A80-F365-4FA0-A625-AA0E496D9B81Q24273305-C7685009-64AA-4AC5-9BC1-A56F6682276FQ25256700-6FB3CD69-EA94-4E6C-AF42-193295FADD45Q26778003-CAE75ED1-06DF-4A3D-80A8-FDBB80FB12A5Q26783063-8D820CC8-9BE7-4E7C-A1C6-7F687079DDBAQ27486499-F4F6439C-CE7A-434C-A31E-D38A30C7607EQ27691452-780B9224-889E-49F9-B134-C56375463160Q28393073-41B077C4-9FFD-41FB-B778-0EE062F4D3A6Q33733844-F856D5F1-7FEB-4CE1-BAAB-5BB56DF80A25Q34058804-5FB9422D-42A9-4719-9871-DEFD4CA22F06Q34434866-CFCB893C-D4F5-4517-B92A-D194E67BE280Q34449079-941D868D-AB41-409A-BA7B-9AAE0A9CC593Q34460182-09232E55-529C-4185-BFBC-8C5E3944B35CQ34686400-8534D921-9A3F-40DB-9502-C1FAC2147DD4Q34717923-225F04F3-3AE8-45F6-90B6-4A8F9537B961Q34792924-CC9F931E-4D57-4270-A339-6FBD1325214DQ35066000-3FD96C14-9239-46E6-B2C7-7A692B4EAC73Q35260239-B1193C32-3A63-4F3C-8839-CAF67EC461EAQ35299783-C777A52F-CA60-40BC-A2F5-864D3547F508Q35654347-5B982D5E-90ED-41F7-95BA-928DA8D65C44Q35684876-9CBD8778-7E05-4BB8-B538-91C44A245150Q36043296-5F4FCE8B-A706-4C58-9B91-38169D03F02AQ36100545-BC66C9F9-6060-46AF-A088-D5F6E4B98635Q36378625-971EBC98-AC8D-4798-9CB3-C4D7335E4B8FQ36399839-0745265C-8ABA-4115-AA6B-BF16E9C290C8Q36827365-02A22E42-784F-4ABA-AC60-EFA658253C63Q37163676-FD98E1E2-542F-44F9-A711-8AAD086E1E27Q37504760-53DA35CE-B8BE-4B06-B2D8-19E40FB9A148Q37945233-DDDDC521-4E3F-4560-9A92-86C502079CB9Q37976671-6EE09C3C-3024-4446-AEEB-EE94C75A37FAQ38205274-7E840D03-3D6C-43C1-B335-849B8EED27E9Q38500788-223EA9EC-3709-41BD-82F3-5D621FE4C1BBQ38579449-F0BAF7FC-4DD6-4C66-8987-6142E3703AEAQ38707770-A685EE53-58A2-4F96-B984-2C5923FE34BBQ38711125-1BBDE29B-B19D-4D0B-9E95-9421A701694AQ38848208-D809FFB6-30D4-4454-A4A7-8241A7C0C409Q39157055-92EEFDAF-B1A1-4529-BC6B-FD9893FC0ECDQ39715538-1CC666B4-0CBD-4222-82EF-F59A9B28EBFDQ40051414-2F18E747-4DD4-412C-BEB5-51043A280D23Q40094833-57F9B6D6-9FAB-4F88-97D1-44CDEC49981E
P2860
Early immune responses accompanying human asymptomatic Ebola infections
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Early immune responses accompanying human asymptomatic Ebola infections
@ast
Early immune responses accompanying human asymptomatic Ebola infections
@en
Early immune responses accompanying human asymptomatic Ebola infections
@nl
type
label
Early immune responses accompanying human asymptomatic Ebola infections
@ast
Early immune responses accompanying human asymptomatic Ebola infections
@en
Early immune responses accompanying human asymptomatic Ebola infections
@nl
prefLabel
Early immune responses accompanying human asymptomatic Ebola infections
@ast
Early immune responses accompanying human asymptomatic Ebola infections
@en
Early immune responses accompanying human asymptomatic Ebola infections
@nl
P2093
P2860
P1476
Early immune responses accompanying human asymptomatic Ebola infections
@en
P2093
E Mavoungou
J Lansoud-Soukate
P2860
P304
P356
10.1046/J.1365-2249.2001.01517.X
P407
P577
2001-06-01T00:00:00Z